Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance.
Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996.
Dr. Lederman represented U.S. Biotechnology at a Beijing Summit in September 2015 with China’s President Xi Jinping. The Summit was organized by the U.S. Chamber of Commerce and involved a delegation of U.S. CEOs, former U.S. Cabinet officials and leading academic experts.
Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.
Dr. Sullivan is a physician and scientist. Dr. Sullivan joined Tonix Pharmaceuticals from Columbia University (CU), where he was most recently an Assistant Professor of Psychiatry in the Department of Psychiatry at Columbia University Medical Center, a Research Scientist at the New York State Psychiatric Institute (NYSPI) and as a practicing psychiatrist. His areas of expertise include the diagnosis, treatment and neurobiology of anxiety and mood disorders, including PTSD. As Principal Investigator and Co-Investigator on several human studies of PTSD, Dr. Sullivan has administered the recruitment, biological assessments, treatment and safety of participants with PTSD in clinical trials of the disorder. He has served as a member of the Institutional Review Board of the NYSPI since 2009. He has published more than 50 articles and chapters on research topics ranging from stress and anxiety disorders to abnormal serotonergic receptor expression in bipolar depression, PTSD and panic disorder. He is a recipient of grants from the National Institute of Mental Health, the Anxiety Disorders Association of America and the American Foundation for Suicide Prevention. Dr. Sullivan graduated from the University of California, Berkeley where he majored in biological sciences. Dr. Sullivan received his medical doctorate from the College of Physicians & Surgeons at Columbia University and completed his residency training in psychiatry at Columbia University Medical Center. After residency, he continued at CU in an NIMH-sponsored Research Training Fellowship in Affective and Anxiety Disorders. As part of fellowship training, he studied with Dr. Joseph LeDoux at New York University, developing translational animal models of anxiety disorders for preclinical testing of novel anxiolytic therapies. In 2010, he was selected by his peers in psychiatry as one of the 2010 Best Doctors in America.
Bradley Saenger joined Tonix in May 2014, as Director of Accounting (May 2014 – December 2015) and was promoted to VP of Accounting (January 2016 – February 2016) and to Chief Financial Officer (February 2016). Mr. Saenger has more than 10 years’ experience in large publicly-traded companies and an additional 10 years’ experience in public accounting. Between June 2013 and March 2014, Mr. Saenger worked for Shire Pharmaceuticals as a consultant in the financial analyst research and development group. Between February 2013 and May 2013, Mr. Saenger worked for Stewart Health Care System as a financial consultant. Between October 2011 and December 2012, Mr. Saenger was an Associate Director of Accounting at Vertex Pharmaceuticals, Inc. Between January 2005 and September 2011, Mr. Saenger worked for Alere Inc., as a Manager of Corporate Accounting and Consolidations (2007 – 2011) and Manager of Financial Reporting (2005 – 2006). Mr. Saenger also worked for PricewaterhouseCoopers LLP, Shifren Hirsowitz, public accountants and auditors in Johannesburg, South Africa, Investec Bank in Johannesburg, South Africa and Norman Sifris and Company, public accountants and auditors in Johannesburg, South Africa.
Mr. Saenger received his Bachelor’s and Honors’ degrees in Accounting Science from the University of South Africa. Mr. Saenger is a Chartered Accountant in South Africa and a Certified Public Accountant in the Commonwealth of Massachusetts.
Jessica Edgar Morris joined Tonix Pharmaceuticals as Senior Vice President of Finance in September 2013. Ms. Morris served as Acting Chief Financial Officer from January 2016 to February 2016 and was subsequently appointed Executive Vice President, Operations. Ms. Morris has over 10 years of experience in finance and investing, at both private and publicly-traded companies. She was previously a Vice President at Zhong Rong Group, a family office in NYC, where she oversaw the firm's investment strategy and asset allocations. Prior to Zhong Rong Group, Ms. Morris worked at American Capital, a publicly-traded private equity firm and global asset manager, where she sourced and underwrote investments in companies across a range of industries including healthcare. She also worked in an investment capacity at Calvert Street Capital Partners, a private equity firm in Baltimore, MD, as well as Silicon Valley Bank, a senior debt lender to technology and life science companies. Ms. Morris began her career at Deutsche Bank as an investment banking financial analyst. Ms. Morris received a B.S. in Commerce and B.A in Music from the University of Virginia, where she was an Echols Scholar. Ms. Morris is also a classically trained violinist.
Dr. Edgar brings to Tonix over 25 years of experience in pharmaceutical development and commercialization. He has extensive expertise in advancing research-stage pharmaceutical candidates to commercialization, and has authored chemistry, manufacturing and controls (CMC) strategies for numerous drug development programs. He joins Tonix from M.T. Edgar Consulting, where he provided pharmaceutical development support for over 46 companies, including Tonix, across a wide variety of formulations and therapeutic indications since founding the firm in 2003. From 1995 to 2003, Dr. Edgar held several executive level management positions in the biopharmaceutical industry, including Executive Vice President of Ancile Pharmaceuticals, Senior Vice President of Product Development of La Jolla Pharmaceutical Company and Vice President of Development Research of Syntex Corporation, where he began his industry career as a research chemist.
Dr. Edgar earned his PhD in organic chemistry from Arizona State University and conducted post-doctoral research at both Stanford University and the Universite de Scientifique et Medicale in Grenoble, France. He has authored several peer-reviewed scientific publications. Dr. Edgar also has an MBA from the University of Colorado at Boulder.